

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



LSHTM Research Online

Patel, H; Bell, D; Molokhia, M; Srishanmuganathan, J; Patel, M; Car, J; Majeed, A; (2007) Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998-2005. BMC clinical pharmacology, 7. p. 9. ISSN 1472-6904 <https://researchonline.lshtm.ac.uk/id/eprint/7790>

Downloaded from: <http://researchonline.lshtm.ac.uk/7790/>

DOI:

Usage Guidelines:

Please refer to usage guidelines at <https://researchonline.lshtm.ac.uk/policies.html> or alternatively contact researchonline@lshtm.ac.uk.

Available under license: <http://creativecommons.org/licenses/by/2.5/>

<https://researchonline.lshtm.ac.uk>

Research article

Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998–2005

Hitesh Patel*¹, Derek Bell², Mariam Molokhia³,
Janakan Srishanmuganathan⁴, Mitesh Patel¹, Josip Car⁵ and Azeem Majeed⁵

Address: ¹Charing Cross Hospital, London W6 8RF, UK, ²Chelsea and Westminster Hospital, London SW10 9NH, UK, ³Department of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, WC1E 7HT, UK, ⁴St Mary's Hospital, London W2 1NY, UK and ⁵Department of Primary Care and Social Medicine, Imperial College, London W6 8RF, UK

Email: Hitesh Patel* - dochiteshpatel@hotmail.com; Derek Bell - d.bell@imperial.ac.uk; Mariam Molokhia - mariam.molokhia@lshtm.ac.uk; Janakan Srishanmuganathan - sjanakan@hotmail.com; Mitesh Patel - mitesh.patel@doctors.net; Josip Car - josip.car@imperial.ac.uk; Azeem Majeed - a.majeed@imperial.ac.uk

* Corresponding author

Published: 25 September 2007

Received: 28 November 2006

BMC Clinical Pharmacology 2007, **7**:9 doi:10.1186/1472-6904-7-9

Accepted: 25 September 2007

This article is available from: <http://www.biomedcentral.com/1472-6904/7/9>

© 2007 Patel et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Adverse drug reactions (ADRs) are a frequent cause of mortality and morbidity to patients worldwide, with great associated costs to the healthcare providers including the NHS in England. We examined trends in hospital admissions associated with adverse drug reaction in English hospitals and the accuracy of national reporting.

Methods: Data from the Hospital Episode Statistics database (collected by the Department of Health) was obtained and analysed for all English hospital episodes (1998–2005) using ICD-10 codes with a primary (codes including the words ('drug-induced' or 'due to') or secondary diagnosis of ADR (Y40–59). More detailed analysis was performed for the year 2004–2005

Results: Between 1998 and 2005 there were 447 071 ADRs representing 0.50% of total hospital episodes and over this period the number of ADRs increased by 45%. All ADRs with an external code increased over this period. In 2005 the total number of episodes (all age groups) was 13,706,765 of which 76,692 (0.56%) were drug related. Systemic agents, which include anti-neoplastic drugs, were the most implicated class (15.7%), followed by analgesics (11.7%) and cardiovascular drugs (10.1%). There has been a 6 fold increase in nephropathy secondary to drugs and a 65% decline in drug induced extra-pyramidal side effects. 59% of cases involving adverse drug reactions involved patients above 60 years of age.

Conclusion: ADRs have major public health and economic implications. Our data suggest that national Hospital Episode Statistics in England have recognised limitations and that consequently, admissions associated with adverse drug reactions continue to be under-recorded. External causes of ADR have increased at a greater rate than the increase in total hospital admissions. Improved and more detailed reporting combined with educational interventions to improve the recording of ADRs are needed to accurately monitor the morbidity caused by ADRs and to meaningfully evaluate national initiatives to reduce adverse drug reactions.

Background

Adverse drug reactions cause considerable morbidity and mortality world-wide [1] and in many cases are avoidable. Pirmohamed and colleagues estimated that in England, adverse drug reactions were responsible for around 6.5% of all acute hospital admissions and at least 5,000 deaths per year [2]. In the USA, adverse drug reactions are one of the leading causes of death in the population [3]. Hence, adverse drug reactions have a major impact on public health, reducing patients' quality of life and imposing a considerable financial burden on the health care systems at a time when many health care systems are under considerable financial strain.

Drug reactions can be typically described in two groups. Type A reactions "intrinsic" (which are often dose-dependent) are relatively common. Type B reactions are usually more serious: idiosyncratic reactions that are not necessarily dose-dependent. We expect the majority of ADR admissions to be Type A reactions. Notification to pharmacovigilance agencies (e.g. the Medicines and Healthcare products Regulatory Agency yellow card in the UK) is designed to capture new ADRs not known at the marketing stage, i.e. usually but not exclusively, Type B reactions.

Adverse drug reactions are commonest amongst the elderly [2] This is not surprising as the elderly generally have the highest prevalence of long-term diseases [4]. Poly-pharmacotherapy, combined with a poorer physiological reserve, puts the elderly particularly at risk of adverse drug reactions [5]. Poly-pharmacotherapy amongst elderly patients is likely to increase still further through the implementation of 'pay for performance' schemes, such as the new contract for NHS general practitioners in the UK. This rewards tighter meeting of 'treatment targets' for specific long-term diseases, such as high blood pressure or high cholesterol, which commonly results in prescribing of higher doses of medication or poly-pharmacotherapy with higher number of different medications than in the past.

More evidence-based prescribing for long-term diseases will benefit patients, but may also increase the number of adverse drug reactions in the population merely because of the potential for increased drug reactions. The number of older people in the population of developed countries is also increasing rapidly. For example, in the United Kingdom, the number of people aged 65 years and over is predicted to increase by around 53% between 2001 and 2031 [6]. This increase in the elderly population combined with increased prescribing for long-term diseases is likely to result in an increase in the number of people at risk of suffering from adverse drug reactions.

Despite the importance of adverse drug reactions, methods for monitoring them are limited. Some adverse drug reactions are identified during clinical trials during drug development and testing, however, rare reactions may fail to be detected. Once a drug is marketed, detection of adverse drug reactions generally depends on notifications to regulatory authorities, such as the Medicines and Healthcare products Regulatory Agency, which runs the yellow card scheme in the United Kingdom. However, even for serious and well-recognized ADRs notification of adverse drug reactions from such spontaneous reporting schemes is low, often less than 10% and even lower where the association between the drug and the adverse event is unknown [7].

Hence, many adverse drug reactions do not become apparent until a drug has been in widespread use for several years. Consequently, current systems for the detection of ADRs have serious limitations. For example, the associations between COX-2 inhibitors and increased risk for myocardial infarction and stroke were only highlighted and reviewed after these drugs had been used for several years by hundreds of thousands of patients, although initial concerns were identified from trial data [8].

Other information on adverse drug reactions comes from ad-hoc studies. However, with a few exceptions, such as the study by Pirmohamed and colleagues in North-West England, [2] these previous studies have tended to be small (although with similar results; often based in one hospital) and many are now very old [1].

Hospital Episode Statistics (HES) are collected by the Department of Health and contain details of all admissions to NHS hospitals in England [9]. HES data includes private patients treated in NHS hospitals, patients who were resident outside of England and care delivered by treatment centres (including those in the independent sector) but funded by the NHS. HES were established in 1987 following a report on the collection and use of hospital activity information published by a steering group chaired by Dame Edith Körner [10]. Before 1987, only a 10 per cent sample of admitted patient records were collected nationally whereas HES collect a detailed record for each 'consultant episode' of admitted patient care delivered by NHS hospitals in England.

HES data are available for every financial year from 1989–90 onwards but the dataset has been modified over time to reflect changing administrative requirements and the introduction of new clinical classifications. For example, in 1995, the recording of diagnoses changed from the 9th to the 10th revision of the International Classification of Diseases (ICD) [9]. In the 2004–05 financial year, there

were about 12.1 million hospital admissions, resulting in nearly 14 million consultant episodes, in England.

Waller and colleagues [11], studied HES data from 1996–2000, looking at 258, 222 episodes associated with confirmed ADRs and concluded that HES grossly underestimates the burden of ADRs. As part of preparatory work for projects on the epidemiology of adverse drug reactions, and educational interventions to improve recording of these reactions, we wished to examine the contribution of recorded adverse drug reactions to acute hospital admissions nationally. We aimed to examine the current epidemiology of hospital admission for adverse drug reactions, the age distribution of these admissions, and their impact on hospital activity. We also aimed to compare estimates of hospital admissions due to adverse drug reactions to

those from previous studies to determine how well adverse drug reactions were being recorded in current practice and how much scope there was to improve recording.

Methods

We obtained for the period 1998–2005 from the Department of Health, HES-records in which there was an ICD10 code containing the words 'drug-induced' or which indicated that a diagnosis was 'due to' a drug. We also studied codes in the range Y40 – Y59 ("correct drug properly administered in therapeutic or prophylactic dosage as the cause of any adverse effect"), otherwise known as 'external cause' (Table 1). This excludes accidental or intentional poisoning due to drugs. We studied codes that explicitly stated that the episode was caused by a drug. Thus, we did

Table 1: ICD-10 codes (Y40–Y59) for drugs, medicaments and biological substances causing adverse effects in therapeutic use

ICD-10	External cause mortality/morbidity by:
Y40	Systemic antibiotics: Penicillins, cephalosporins and other beta-lactam antibiotics, chloramphenicol, macrolides, tetracyclines, aminoglycosides, rifamycins, antifungals, others
Y41	Other systemic anti-infectives and antiparasitics: Sulphonamides, other anti-mycobacterial, anti-malarials, anti-protozoal, anti-helminthics, anti-virals
Y42	Hormones and substitutes: Glucocorticoids, thyroid hormones, anti-thyroids, insulin, oral hypoglycaemics, oral contraceptives, oestrogen and progestogen, anti-gonadotrophins, anti-oestrogens, anti-progestogens, androgens
Y43	Systemic agents: Anti-allergic and anti-emetic drugs, anti-neoplastic and immunosuppressive drugs, acidifying/alkalising agents
Y44	Agents affecting blood constituents: Iron preparations, anti-megaloblastic-anaemia preparations, anticoagulants, anticoagulant antagonists, antithrombotic drugs, thrombolytic drugs, blood products, plasma substitutes
Y45	Analgesics, anti-pyretics and anti-inflammatory drugs: Opioids and related analgesics, salicylates, propionic acid derivatives, nonsteroidal anti-inflammatory drugs, antirheumatics, 4-aminophenol derivatives
Y46	Anti-epileptics and anti-parkinsonism drugs: Succinimides, oxazolindiones, hydantoin derivatives, deoxybarbiturates, iminostilbenes, valproic acid, anti-parkinsonism drugs, anti-spasticity drugs
Y47	Sedatives, hypnotics and anti-anxiety drugs: Barbiturates, benzodiazepines, cloral derivatives, paraldehyde, bromine compounds, sedative, hypnotic and antianxiety drug, unspecified
Y48	Anaesthetics and therapeutic gases: Inhaled/parenteral anaesthetics, local anaesthetics, therapeutic gases
Y49	Psychotropic drugs: Tricyclic and tetracyclic antidepressants, monoamine-oxidase-inhibitor, phenothiazine antipsychotics and neuroleptics, butyrophenone and thioxanthene neuroleptics, other antidepressants, antipsychotics and neuroleptics
Y50	Central nervous system stimulants: Analeptics, opioid receptor antagonists, methylxanthines, other central nervous system stimulants
Y51	Drugs primarily affecting the autonomic nervous system: Anticholinesterase agents, cholinergics, ganglionic blocking drugs, anticholinergics, antimuscarinics, spasmolytics, alpha-adrenoreceptor agonists/antagonists, beta-adrenoreceptor agonists/antagonists, centrally acting and adrenergic-neuron-blocking agents
Y52	Agents affecting the cardiovascular system: Cardiac-stimulant glycosides, calcium-channel blockers, other anti-dysrhythmic drugs, other coronary vasodilators, angiotensin-converting-enzyme inhibitors, other anti-hypertensives, anti-hyperlipidaemic and anti-arteriosclerotic drugs, peripheral vasodilators, anti-varicose drugs
Y53	Agents affecting the gastrointestinal system: Antacids, anti-gastric-secretion drugs, laxatives, anti-diarrhoeal, emetics
Y54	Agents affecting water-balance and mineral and uric acid metabolism: Mineralocorticoids, mineralocorticoid antagonists, carbonic-anhydrase inhibitors, benzothiadiazine derivatives, other diuretics, electrolytic, caloric and water-balance agents, agents affecting calcification, agents affecting uric acid metabolism
Y55	Agents acting on smooth and skeletal muscles and the respiratory system: Oxytocic drugs, skeletal muscle relaxants, anti-tussives, expectorants, anti-common-cold drugs, anti-asthmatics
Y56	Topical agents primarily affecting skin and mucous membrane: Local anti-fungal, anti-infective, anti-inflammatory drugs, anti-pruritics, local detergents, emollients, keratolytics, ophthalmological drugs, otorhinolaryngological drugs, dental drugs
Y57	Other and unspecified drugs: Appetite depressants, lipotropic drugs, antidotes and chelating agents, alcohol deterrents, x-ray contrast media, vitamins
Y58	Bacterial vaccines
Y59	Other vaccines: Viral/rickettsial/protozoal vaccines, immunoglobulin

Includes: Correct drug properly administered in therapeutic or prophylactic dosage as the cause of any adverse effect Excludes: Accidental overdose of drug or wrong drug given or taken in error (X40–X44); accidents in the technique of administration of drugs, medicaments and biological substances in medical and surgical procedures (Y60–Y69)

not include conditions like toxic epidermal necrolysis, which is invariably drug induced but does have other known causes.

HES records contain a main diagnosis field and up to 13 secondary diagnosis fields (seven before 2002/3). We examined the number of episodes per year and for the most recent year for which data was available (2004/05); we also examined several other measures, including the number of admissions by age and the total bed days used by patients with diagnoses of adverse drug reactions. An episode is defined as the time a patient spends under the care of one consultant. Most admissions result in just one episode of care and hence episodes are a reasonably good proxy for admissions.

HES data is collected in financial year from 1 April to 31 March the following year. Our data is presented in this format. HES data is collected comprehensively and undergoes extensive processing and validation to maintain quality. This process is detailed on their official website [9]. Some of the data presented changed classification during the time period and it became dubious whether the episode was related exclusively to an ADR. These data were not included and are marked as U/C (unclassified) in the tables.

Results

Overall burden of hospital admissions for ADRs

Table 2 summarises the total number of episodes and the total number of episodes associated with ADRs. In our seven year study period, there were 88,822,005 total hospital episodes and 447,041 episodes with a diagnostic code indicative of ADRs (0.5%). Of these 68,971 (0.08%) were primary diagnoses and 378,070 (0.4%) were of 'external cause'.

Change in burden

Between 1998–2005, the total number of hospital episodes increased by 14% but the total number of reported episodes linked with ADRs increased by 45% (largely due to an increase in external cause codes). Table 3 and 4 highlight the burden of ADRs according to ICD-10 code. Drug induced haemolytic anaemia (927%), nephropathy (590%), adrenocortical failure (146%), cardiomyopathy

(144%) and aplastic anaemia (139%) were the five fastest growing ADRs as a primary diagnosis (Table 3). In contrast, the top five fastest growing ADRs as external causes were drugs relating to: water balance (164%), autonomic system (108%), central nervous system stimulants (102%), cardiovascular system (92%) and biologicals/vaccines (77%). Primary diagnosis of ADRs decreased by 1% during this study. Reported rates under the categories of 'drug-induced extra-pyramidal side effects' (-65%) and 'malignant hyperpyrexia' (-33%) showed the largest declines (Table 3).

Detailed overview for 2004–5

In 2004, there were 10,396 (0.08%) ADR admissions associated with a primary diagnosis and 66,296 (0.5%) ADRs as a secondary cause. Combined, they account for 0.56% of hospital episodes. The three commonest classes of adverse drug reaction, classified as an external cause (Table 4) resulting in hospital admission were systemic agents (Y43); analgesics, antipyretics and anti-inflammatory drugs (Y45); and systemic antibiotics (Y40). 'Mental disorders' secondary to opioids and psychoactive drugs reflected 63% of all the primary diagnoses of ADR (Table 3).

Most hospital episodes associated with adverse drug reactions occurred in the elderly. In 2004–5, 59% of hospital episodes in which there was an external ICD10 code for an adverse drug reaction occurred in people aged 60 years and over. The mean age of ADRs was 60 (Table 5, 6). Younger patients tended to have ADRs from vaccines and psychoactive drugs.

The majority of adverse drug reactions were reported in females (58%). By contrast, females accounted for 51% of all hospital admissions in 2004–05. Men were more likely to suffer from mental disorders due to psychoactive drugs and women were more likely to suffer from drug induced nephropathy and systemic lupus erythematosus. On average, each episode associated with an adverse drug reaction required a hospital admission lasting 9.7 days (compared with 7.1 days as the mean length of stay for admissions due to any cause). Episodes with a record of an adverse drug reaction accounted for 0.8% (439,685/54,554,697) of total bed days in 2004–05.

Table 2: Total number of Hospital Episode Statistics for which there was a primary diagnosis or 'external cause' of ADR 1998–2005

	1998–9	1999–00	2000–1	2001–2	2002–3	2003–4	2004–5	% Change 1998–2005
Total No. of Episodes	11,983,893	12,167,574	12,674,277	12,357,360	12,757,656	13,174,480	13,706,765	14.4
No. with 'drug induced' codes	10506	10105	9823	9442	9246	9453	10396	-1.0
No. with external cause codes	42,555	47,385	50,113	52,160	56,943	62,618	66,296	55.8
Total Adverse Drug Reactions	53,061	57,490	59,936	61,602	66,189	72,071	76,692	44.5

Table 3: Annual number of Hospital Episode Statistics finished consultant episodes with a primary diagnosis for an ADR (ICD-10 code)

ICD-10	1998-9	1999-00	2000-1	2001-2	2002-3	2003-4	2004-5	% Change 1998-2005
D59.0/2 Drug induced haemolytic anaemia	15	30	28	37	34	36	154	926.7
D61.1 Drug induced aplastic anaemia	101	116	114	186	182	162	241	138.6
E03.2 Hypothyroidism due to medicaments	23	23	12	12	19	13	26	13.0
E27.3 Drug induced adrenocortical failure	24	22	24	38	39	53	59	145.8
F11 Mental disorders due to opioids	4360	4287	4398	4187	3916	3690	3746	-14.1
F13 Mental disorders due to sedatives/hypnotics	223	247	247	239	232	206	189	-15.2
F19 Mental disorders due to multiple psychoactive drugs	3513	3137	2725	2643	2601	2690	2775	-21.0
G21.0 Malignant neuroleptic syndrome	101	106	121	108	102	93	128	26.7
G21.1 Drug induced Parkinsonism	145	115	124	133	112	108	149	2.8
G24.0 Drug induced dystonia	149	130	145	130	115	152	109	-26.8
G25.1/4/6 Drug induced extrapyramidal syndrome/chorea/tics	136	146	110	125	44	51	48	-64.7
G72.0 Drug induced myopathy	47	53	51	51	57	39	55	17.0
H91.0 Ototoxic hearing loss	2	5	3	3	2	U/C ¹	U/C	U/C
I42.7 Drug induced cardiomyopathy	25	25	53	38	67	77	61	144.0
J70.2/3/4 Drug induced interstitial lung disorders	54	45	43	43	86	71	94	74.1
K71 Drug induced liver disease	406	318	372	351	459	437	448	10.3
L56.0/1 Drug induced phototoxicity	4	5	2	4	1	3	5	25.0
M10.2 Drug induced gout	30	27	13	24	22	22	34	13.3
M32.0 Drug induced systemic lupus erythematosus	17	20	12	13	14	10	26	52.9
M34.2 Drug induced systemic sclerosis	3	3	4	3	U/C	U/C	U/C	U/C
N14 Drug induced nephropathy	60	69	92	85	100	318	414	590.0
T88.3 Malignant hyperthermia due to anaesthesia	6	4	10	3	3	5	4	-33.3
T88.6 Drug induced anaphylaxis	366	435	399	384	375	469	563	53.8
T88.7 Unspecified adverse drug effect	696	737	721	602	664	748	1068	53.4
Total	10506	10105	9823	9442	9246	9453	10396	-1.0

¹U/C – unclassified: data not available due to a coding change

Table 4: Annual number of HES finished consultant episodes with an 'external code' for an adverse drug reaction

ICD-10	1998-9	1999-00	2000-1	2001-2	2002-3	2003-4	2004-5	% Change 1998-2005
Y40 Systemic antibiotics	4,206	4,212	4,533	4,341	4,697	5,624	6,449	53.3
Y41 Other systemic anti-infectives/anti-parasitics	829	816	1,017	945	1,195	1,134	1,453	75.3
Y42 Hormones (including synthetic, antagonists)	4,547	5,088	4,934	5,113	5,803	5,461	5,319	17
Y43 Primarily systemic agents	7,501	8,271	9,078	9,877	10,766	11,226	12,054	60.7
Y44 Agents primarily affecting blood constituents	4,062	4,483	4,723	4,797	5,230	5,995	4,272	5.2
Y45 Analgesics/antipyretics/anti-inflammatory	5,951	6,726	6,787	6,819	7,540	8,079	9,004	51.3
Y46 Antiepileptics/antiParkinsonism drugs	1,230	1,267	1,224	1,340	1,401	1,501	1,628	32.4
Y47 Sedatives, hypnotics, anti-anxiety drugs	370	400	450	430	480	586	560	51.4
Y48 Anaesthetics, therapeutic gases	414	538	502	440	505	521	531	28.3
Y49 Psychotropic drugs	1,653	1,678	2,008	1,992	1,953	2,364	2,544	53.9
Y50 Central nervous system stimulants	46	67	75	76	69	71	93	102.2
Y51 Drugs affecting autonomic nervous system	1,702	2,056	2,277	2,470	2,686	3,239	3,532	107.5
Y52 Agents primarily affecting cardiovascular system	4,044	4,752	5,376	5,667	6,234	6,836	7,768	92.1
Y53 Agents primarily affecting gastrointestinal system	398	410	486	416	461	579	656	64.8
Y54 Agents affecting water/mineral balance/uric acid	2,136	2,617	2,945	3,526	4,151	5,118	5,638	164
Y55 Agents affecting muscle/respiratory system	312	299	342	321	323	430	422	35.3
Y56 Topical agents affecting skin/ENT, dental	1,138	1,236	983	1,202	1,065	1,079	1,224	7.6
Y57 Other and unspecified medicaments	1,524	1,715	1,780	1,907	1,906	2,014	2,398	57.3
Y58 Bacterial vaccines	226	347	255	182	197	356	281	24.3
Y59 Other vaccines/biologicals	266	407	338	299	281	405	470	76.7
Total	42,555	47,385	50,113	52,160	56,943	62,618	66,296	55.8

Table 5: Number of HES finished consultant episodes with a primary diagnosis of an ADR in 2004/05: mean age of admissions, age & gender distribution of episodes and total bed days

ICD-10		Male %	Mean age	Age 0–14 (%)	Age 15–59 (%)	Age 60–74 (%)	Age 75+ (%)	Total Bed days
D59.0/2	Drug induced haemolytic anaemia	49	63	0 (0.0)	52 (0.5)	75 (0.8)	27 (0.3)	160
D61.1	Drug induced aplastic anaemia	49	64	2 (0.0)	89 (0.9)	74 (0.7)	73 (0.7)	604
E03.2	Hypothyroidism due to medicaments	42	72	0 (0.0)	6 (0.1)	3 (0.0)	17 (0.2)	191
E27.3	Drug induced adrenocortical failure	41	48	11 (0.1)	22 (0.2)	12 (0.1)	14 (0.1)	584
F11	Mental disorders due to opioids	66	32	14 (0.1)	3681 (36.9)	33 (0.3)	14 (0.1)	47390
F13	Mental disorders due to sedatives/hypnotics	54	47	6 (0.1)	123 (1.2)	33 (0.3)	27 (0.3)	4922
F19	Mental disorders due to multiple psychoactive drugs	75	31	14 (0.1)	2734 (27.4)	17 (0.2)	10 (0.1)	64152
G21.0	Malignant neuroleptic syndrome	67	50	0 (0.0)	88 (0.9)	28 (0.3)	12 (0.1)	2,315
G21.1	Drug induced Parkinsonism	43	77	1 (0.0)	11 (0.1)	44 (0.4)	93 (0.9)	1,964
G24.0	Drug induced dystonia	47	43	10 (0.1)	65 (0.7)	16 (0.2)	18 (0.2)	550
G25.1/4/6	Drug induced extrapyramidal syndrome/chorea/tics	40	64	2 (0.0)	15 (0.2)	18 (0.2)	13 (0.1)	407
G72.0	Drug induced myopathy	51	65	1 (0.0)	12 (0.1)	20 (0.2)	22 (0.2)	517
H91.0	Ototoxic hearing loss	U/C	U/C	U/C	U/C	U/C	U/C	U/C
I42.7	Drug induced cardiomyopathy	48	43	7 (0.1)	42 (0.4)	7 (0.1)	5 (0.1)	376
J70.2/3/4	Drug induced interstitial lung disorders	49	64	3 (0.0)	24 (0.2)	40 (0.4)	27 (0.3)	858
K71	Drug induced liver disease	43	47	12 (0.1)	315 (3.2)	50 (0.5)	71 (0.7)	3408
L56.0/1	Drug induced phototoxicity	0	47	1 (0.0)	2 (0.0)	2 (0.0)	0 (0.0)	17
M10.2	Drug induced gout	53	75	0 (0.0)	4 (0.0)	9 (0.1)	21 (0.2)	237
M32.0	Drug induced systemic lupus erythematosus	27	43	0 (0.0)	19 (0.2)	2 (0.0)	5 (0.1)	69
M34.2	Drug induced systemic sclerosis	U/C	U/C	U/C	U/C	U/C	U/C	U/C
N14	Drug induced nephropathy	2	58	0 (0.0)	3 (0.0)	5 (0.1)	3 (0.0)	111
T88.3	Malignant hyperthermia due to anaesthesia	75	20	2 (0.0)	2 (0.0)	0 (0.0)	0 (0.0)	8
T88.6	Drug induced anaphylaxis	37	52	19 (0.2)	326 (3.3)	130 (1.3)	87 (0.9)	883
T88.7	Unspecified adverse drug effect	33	50	80 (0.8)	565 (5.7)	203 (2.0)	217 (2.2)	2,471
Total		33	40	185 (1.9)	8200 (82.1)	821 (8.2)	776 (7.8)	132194

Table 6: Number of HES finished consultant episodes with an external ICD10 cause for an adverse drug reaction in 2004/05: mean age of admissions, age & gender distribution of episodes and total bed days

ICD-10	Male %	Mean age	Age 0–14 (%)	Age 15–59 (%)	Age 60–74 (%)	Age 75+ (%)	Total bed days
Y40 Antibiotics	40	57	467 (0.7)	2468 (3.7)	1433 (2.2)	2064 (3.1)	48,868
Y41 Other anti-infectives	39	55	48 (0.1)	776 (1.2)	245 (0.4)	362 (0.5)	9,280
Y42 Hormones	37	61	173 (0.3)	2051 (3.1)	1571 (2.4)	1513 (2.3)	31,323
Y43 Systemic agents	46	52	1475 (2.2)	5123 (7.7)	4107 (6.2)	1323 (2.0)	83,049
Y44 Blood constituents	47	70	37 (0.1)	830 (1.3)	1331 (2.0)	2072 (3.1)	31,919
Y45 Analgesics, antipyretics, anti-inflammatory	44	66	101 (0.2)	2756 (4.2)	2392 (3.6)	3746 (5.7)	50,118
Y46 Antiepileptics, antiparkinsonism	51	59	69 (0.1)	641 (1.0)	434 (0.7)	484 (0.7)	15,002
Y47 Sedatives, hypnotics, anti-anxiety	43	56	54 (0.1)	210 (0.3)	104 (0.2)	190 (0.3)	4,782
Y48 Anaesthetics, therapeutic gases	47	50	32 (0.0)	275 (0.4)	145 (0.2)	78 (0.1)	2,263
Y49 Psychotropic drugs	39	65	33 (0.0)	822 (1.2)	610 (0.9)	1076 (1.6)	25,733
Y50 Central nervous system stimulants	46	51	6 (0.0)	47 (0.1)	17 (0.0)	23 (0.0)	404
Y51 Autonomic nervous system	49	73	16 (0.0)	473 (0.7)	1037 (1.6)	2006 (3.0)	16,886
Y52 Cardiovascular system	47	75	15 (0.0)	870 (1.3)	2210 (3.3)	4669 (7.1)	48,189
Y53 Gastrointestinal system	39	62	30 (0.0)	222 (0.3)	163 (0.2)	239 (0.4)	3,597
Y54 Water-balance, mineral and uric acid	33	77	13 (0.0)	411 (0.6)	1360 (2.1)	3848 (5.8)	42,568
Y55 Smooth/skeletal muscle, respiratory system	39	56	24 (0.0)	182 (0.3)	105 (0.2)	111 (0.2)	2,232
Y56 Topical agents	42	58	68 (0.1)	459 (0.7)	344 (0.5)	351 (0.5)	5,779
Y57 Other unspecified drugs	43	60	87 (0.1)	894 (1.4)	649 (1.0)	760 (1.1)	15,835
Y58 Bacterial vaccines	52	10	243 (0.4)	15 (0.0)	14 (0.0)	9 (0.0)	296
Y59 Other vaccines, biological substance	51	28	211 (0.3)	162 (0.2)	57 (0.1)	40 (0.1)	1,562
Total	43	63	3202 (4.8)	19687 (29.7)	18328 (27.7)	24964 (37.7)	439,685
Combined Primary Diagnosis and External Cause	42	60	3387 (4.4)	27887 (36.6)	19149 (25.1)	25740 (33.8)	571,879

Discussion

This national study on time trends for hospital admissions for adverse drug reactions in England is unique in covering such a large population and for such long time period. Our data show that the number of admissions linked to adverse drug reactions has increased substantially over the time period covered by the study.

The reported increase of ADRs by 45% may be accounted by improving record keeping due to increased awareness, a general increase in ADRs against a background of an increasingly elderly population, the introduction of new drugs and poly-pharmacotherapy because of increased pressure to prescribe medication for chronic diseases. For example, Swedish studies have shown a substantial increase over the last 30 years in the average number of drugs prescribed to patients who were admitted to hospital because of an ADR [12,13]. Our data shows a continuation of the trends in Waller's and colleague's paper, which reported a 40% increase in ADRs between 1996–2000. When interpreting any results, we must bear in mind the limitations of this study, which are outlined below. However, even in 2004/05, adverse drug reactions accounted for only about 0.56% of all emergency hospital episodes in that year. This is substantially less than the 5% of emergency hospital admissions generally quoted from other studies, suggesting there is considerable under-recording of adverse drug reactions in routine hospital activity data.

The strengths of our study over earlier work include its longitudinal nature and its completeness in that it covers all NHS hospital admissions in England. All submitted HES data are verified, validated and where appropriate overwritten to maintain accuracy. Furthermore, the data are compared with the independent Körner aggregate returns (KP 70) to ensure that all consultant episodes are captured [14]. However, our data has the weaknesses associated with routinely collected data, such as missing, incomplete or inaccurate data. It is likely that the effects of these would lead us to under-estimate the true burden of ADRs on the NHS. HES data are also collected locally at hospitals in a process that involves different coders and clinicians, and this may introduce variability in coding practice between hospitals. Consequently, there are errors in HES data with, for example, up to 22% error rates in codes reported in plastic surgery [15]. Despite this, HES remain a key source of information on hospital activity in England's NHS. We did not have access to mortality data associated with our hospital episodes, which would have given more insight into the severity of ADRs associated with hospital admissions.

Potential sources of bias

We do not have data on the total number of each drug group prescribed and hence we are unable to conclude whether adverse drug reactions were more common with certain drug groups because they are prescribed more often or whether the drugs are more likely to lead to an adverse event. The number of admissions is likely to reflect a combination of these two factors. For example, the increase in admissions due to agents affecting the cardiovascular system (Y52) may reflect increased use of these drugs to treat conditions such as hypertension or heart failure in the general population.

The number of medications a patient takes is associated with the risk of an adverse drug reaction, with the mean rate increasing by 10% with each extra medication prescribed [16]. HES data does not allow us to monitor the effects of poly-pharmacotherapy on adverse drug reaction trends directly. This could be done by using data from computerised primary care records held by general practitioners.

We did not have access to the raw data and thus were not able to identify duplicates, which is another limitation of HES data. However, the purpose of this study was to see whether the freely available data (without further data manipulations) from HES has a role in monitoring ADRs and evaluating interventions to reduced ADRs.

Comparison with other studies

Overall trends

There are limited recent studies examining the epidemiology of adverse drug reactions, especially in England [1]. Pirmohamed et al undertook a 6 month prospective study of admissions to two North England hospitals. However, even their study, which is widely cited and regarded as one of the best sources of information on the epidemiology of adverse drug reactions, reported on only 1225 admissions linked to adverse drug reactions. Their estimate of that 6.5% of emergency admissions were associated with adverse drug reactions may be an over-estimate because they excluded groups such as children, women presenting with obstetrics and gynaecological problems; both women of child-bearing age and women are likely to have relatively few admissions due to adverse drug reactions. A recent two year survey of the National Electronic Surveillance – All Injury Programme (NEISS-AIP) consisting of 63 US hospitals that are nationally representative, which analysed over 21 000 emergency department visits due to adverse drug reactions over two years, estimated they accounted for 0.6% of all emergency department visits [17].

Our estimates of ADRs from HES suggest an under-reporting in concordance with the conclusions of Waller and

colleagues [11]. Our data showed a higher incidence of ADRs than Waller's study, which is difficult to explain. It may represent an increasing trend in ADRs, better record keeping, or improved vigilance. The present study does show emerging trends of drug induced nephropathy and reduced incidence of side effects from Parkinson's disease. We could theorise reasons for this but it would be difficult to interpret without knowing the specific medicines causing these trends.

In the two most recent studies, length of stay in patients with adverse drug reactions was 8 (median) [2] and 10.6 (mean) [3] days and is longer than current average hospital stays. Our study gives a similar mean value. The cost of a hospital bed in the UK is €228 per day [18], however, it is difficult to estimate the exact cost associated with hospital episode related adverse drug reactions, given the degree of underreporting. Shorter hospital stays may lead to underreporting of adverse drug reactions.

Age

The elderly are known to experience more type A drug reactions (predictable reactions related to the pharmacodynamics of the drug) [5]. The NEISS-AIP paper found that individuals over 65 years of age accounted for 50% of all hospitalisations for an adverse drug reactions [12], which is comparable to our figure of 65% for people over 60 (21% of the UK population).

The largest burden of ADRs in the 0–14 year age group (44%) was with systemic agents. Approximately 42% of paediatric prescriptions are 'off-label' (drug use outside its licence) and these are more likely to cause ADRs [19]. It should be possible to examine if the availability of new prescribing guidelines following the publication of the specific British National Formulary for Children in 2005 has had an effect on ADRs and off label drug use in this cohort.

Sex

Pirmohamed et al. reported that 59% the patients admitted with an adverse drug reaction were female. Our data provides further support to this. Further research to elucidate whether this relationship occurs because women are more likely to develop adverse drug reactions or because women are more likely to report adverse drug reactions is needed. It is widely known that women tend to present more to their doctors for treatment and consequently would be expected to experience more ADRs, however, our data showed that for non-ADR causes women had a similar number of hospital episodes as men. Rademaker has suggested that pharmacological, immunological and hormonal differences and the fact that women take more medications may explain some gender differences [20].

Major drug groups

Systemic agents (Y43), which includes cancer chemotherapy, were the most common cause of admissions in our study, similar to the findings of Waller and colleagues [11]. This will require further attention as estimates of the life time risk of cancer are reported to be 1 in 3 [21]. Increase in ADRs may also be due to more aggressive management made permissible by bone marrow rescue with growth colony stimulating factors (neutropenia is a common serious side effect of chemotherapy). The only other comparable study to ours in terms of size and generalisability is the US NEISS-AIP [13]. Even though their therapeutic drug categories are different to ours, their top five classes included (in brackets are approximately equivalent ICD-10 codes): central nervous system agents (Y45–50), antimicrobial agents (Y40–1), hormone modifying agents (Y42), haematological and oncology agents (Y43–4) and cardiovascular agents (Y52), which is broadly similar to findings using HES data for England.

Implications for policy & conclusions

Adverse drug reactions have major clinical, public health and economic implications but our data suggest that admissions associated with adverse drug reactions are not being well recorded by NHS hospitals in England. A key requirement would be to include more detailed breakdown of drugs implicated in ADRs. Several European countries also include causality assessment criteria by which likelihood of ADR being related to a particular drug can be estimated. Other suggestions include linking these episodes to prescribing in primary care or pharmacies.

The current deficiencies in routine systems for monitoring ADRs have several important implications. Firstly, the NHS is not able to monitor accurately the burden of ill-health and mortality, or the financial costs, of adverse drug reactions. Secondly, potentially valuable information that could help us understand the aetiology of adverse drug reactions and identify patients for further studies (for example pharmacogenetic studies), is not being recorded. Finally, if accurate information on admissions due to adverse drug reactions is not available, then the NHS can not assess the impact of interventions to improve prescribing. There is strong support for such interventions but if they are introduced, without accurate routine information on the burden of adverse drug reactions, we have no way of measuring their clinical and their cost effectiveness.

Locally, we are developing educational interventions and mechanisms to feedback information on rates of correct medical prescribing, drug interactions and of recording of adverse drug reactions to hospital doctors and clinical coders in hospitals linked to Imperial College's School of Medicine. We will be evaluating the impact of such inter-

ventions on the recording of adverse drug reactions and using the information generated to develop and monitor the impact of preventive strategies to prevent such events. Hospitals in other areas should also consider adopting their own interventions to improve the identification and coding of admissions linked to adverse drug reactions.

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

AM, DB, JC conceived the study, acted as supervisors and made critical contributions to the manuscript at each stage. HP, MP and JS obtained and analysed the data, and prepared the initial drafts. MM contributed significantly to revisions.

References

1. Wiffen P, Gill M, Edwards J, Moore A: **Adverse drug reactions in hospital patients. A systematic review of the prospective and retrospective studies.** *Bandolier Extra* 2002:1-16.
2. Pirmohamed M, James S, Meakin S, Green C, Scott A, Walley T, Farrar K, Park K, Breckenridge A: **Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients.** *BMJ* 2004, **329**:15-19.
3. Lazarou J, Pomeranz B, Corey P: **Incidence of adverse drug reactions in hospitalised patients. A meta-analysis of prospective studies.** *JAMA* 1998, **279**(15):1200-1205.
4. Key Health Statistics from General Practice 1998: 2000 [<http://www.statistics.gov.uk/statbase/Product.asp?vlnk=4863>]. Office for National Statistics, London (last accessed November 23, 2006).
5. Leach S, Roy S: **Adverse drug reactions: an investigation on an acute geriatric ward.** *Age Ageing* 1986, **15**(4):241-6.
6. Majeed A, Aylin P: **The ageing population of the United Kingdom and cardiovascular disease.** *BMJ* 2005, **331**:1362.
7. Stephens M: **Introduction.** In *Stephens' Detection of New Adverse drug Reactions* 5th edition. Edited by: Talbot J, Waller P. John Wiley & Sons Ltd; 2005:10-7.
8. Konstam M, Weir M, Reicin A, Shapiro D, Sperling R, Barr E, Gertz B: **Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.** *Circulation* **104**(19):2280-8. 2001 Nov 6;
9. Department of Health: [<http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&categoryID=87>]. (last accessed November 25, 2006)
10. Lee F, Patel H, Emberton M: **The 'top 10' urological procedures: a study of hospital episode statistics 1998-1999.** *BJUI* 2002, **90**:1-6.
11. Waller P, Shaw M, Davidson H, Shakir S, Ebrahim S: **Hospital admissions for 'drug-induced' disorders in England: a study using the Hospital Episodes Statistics (HES) database.** *British Journal of Clinical Pharmacology* 2004, **59**:213-219.
12. Beermann B, Biorck G, Groschinsky-Grind M: **Adverse drug reactions and poisoning as a cause of admission to a medical clinic.** *Lakartidningen* 1978, **75**(10):958-60.
13. von Euler M, Eliasson E, Ohlen G, Bergman U: **Adverse drug reactions causing hospitalization can be monitored from computerized medical records and thereby indicate the quality of drug utilization.** *Pharmacoepidemiol Drug Saf* 2006, **15**(3):179-84.
14. Lee F, Patel H, Emberton M: **The 'top 10' urological procedures: a study of hospital episode statistics 1998-1999.** *BJUI* 2002, **90**:1-6.
15. Colville R, Laing J, Murison M: **Coding plastic surgery operations: an audit of performance using OPCS-4.** *British Journal of Plastic Surgery* 2000, **53**:420-2.
16. Gandhi T, Weingart S, Borus J, Seger A, Peterson J, Burdick E, Seger D, Shu K, Federico F, Leape L, Bates D: **Adverse drug events in ambulatory care.** *N Engl J Med* 2003, **348**:1556-64.

17. Budnitz D, Pollock D, Weidenbach K, Mendelsohn A, Schroeder T, Annett J: **National surveillance of emergency department visits for outpatient adverse drug events.** *JAMA* 2006, **296**:1858-1866.
18. Chartered Institute of Public Finance and Accountancy (CIPFA): *The health service financial database and comparative tool* Croyden: Institute of Public Finance; 2002.
19. Ufer M, Kimland E, Bergman U: **Adverse drug reactions and off label prescribing for paediatric outpatients: a one year survey of spontaneous reports in Sweden.** *Pharmacoepidemiology and Drug Safety* 2004, **13**:147-152.
20. Rademaker M: **Do women have more adverse drug reactions?** *American Journal of Clinical Dermatology* 2006, **2**:349-351.
21. Office of National Statistics: [<http://www.statistics.gov.uk/cci/nugget.asp?id=915>]. (last accessed November 25, 2006)

Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1472-6904/7/9/prepub>

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

